See original here: Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
See original here: Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
Read more here: Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
Read the rest here: Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
The rest is here: Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Read the original: Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
See the article here: Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
Continue reading here: Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
The rest is here: Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023
Follow this link: Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France
Read more: Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
Recent Comments